DET

Discovery

DET was first synthesized by Hungarian chemist and psychiatrist Stephen Szára in 1956 at the National Institute for Nervous and Mental Diseases in Budapest.^[1] Szára self-administered 60 mg intramuscularly as part of a systematic investigation of tryptamine derivatives.^[7][1] The first formal clinical study, published in 1959 by Böszörményi, Dér, and Nagy in the Journal of Mental Science, administered DET to institutionalized psychiatric patients — conditions later characterized as oppressive, producing predominantly anxious responses.^[3][5]

Clinical and cultural significance

DET's investigation occurred during the broader mid-twentieth-century era of psycholytic therapy, when numerous tryptamine and lysergamide compounds were explored in European psychiatric settings.^[8] Early studies established that its effects were broadly similar to but milder than LSD, encompassing visual phenomena and altered perception of time and space.^[7] Alexander Shulgin independently documented DET as entry #3 in TiHKAL (1997), providing synthesis routes, dosing parameters, and collected experience narratives.^[5]

Prohibition and modern status

DET was placed on Schedule I of the 1971 Convention on Psychotropic Substances, one of only five tryptamines under international control alongside DMT, etryptamine, psilocin, and psilocybin.^[4] No modern controlled clinical trial has been initiated. The compound remains a historical footnote in psychedelic pharmacology — one of the earliest tryptamines characterized in humans, yet among the least studied in the contemporary research renaissance.

Structural class

DET belongs to the N,N-dialkyltryptamine family, built on the indole-ethylamine scaffold shared by all substituted tryptamines. Two ethyl groups on the terminal nitrogen distinguish it from DMT (two methyl groups), DPT (two propyl groups), and DiPT (two isopropyl groups).^[9]

The N-ethyl groups create greater steric bulk than DMT's methyl groups, reducing susceptibility to MAO-A-mediated breakdown and accounting for DET's oral activity without MAOI co-administration.^[1] Within the hallucinogenic tryptamine series, this N,N-dialkyl substitution pattern is critical for psychedelic activity at the 5-HT₂A receptor.^[10]

Molecular properties

The molecule comprises an unsubstituted indole ring connected via an ethyl bridge to the diethylamino nitrogen.^[9] DET contains no chirality centers and exists as a single achiral compound.

Physical properties

Physical property data derive from Shulgin's documentation^[5] and secondary sources.^[1] Boiling point, density, precise aqueous solubility, and degradation pathway data have not been published.

Mechanism of action

DET produces its psychedelic effects primarily through agonism at the serotonin 5-HT₂A receptor, activating the Gq signaling pathway and triggering downstream phosphoinositide hydrolysis.^[2] This Gq-coupled pathway — rather than β-arrestin2 recruitment — determines psychedelic potential, as demonstrated in mouse models where a threshold of 5-HT₂A-Gq activation was required to produce hallucinogenic behavioral responses.^[11]

DET is orally active without MAOI co-administration, unlike DMT. The two N-ethyl groups slow MAO-A-mediated breakdown in the gut and liver sufficiently for intact compound to reach the brain at psychoactive concentrations.^[1] This is a pharmacokinetic distinction — both DET and DMT target the same primary receptor.

Repeated 5-HT₂A activation induces rapid downregulation and tolerance, a mechanism shared across classical psychedelics and driven by receptor internalization rather than β-arrestin2-dependent pathways.^[6]

Pharmacokinetics

No published human pharmacokinetic study exists for DET. All available data derive from historical clinical observations and community reports.

Oral onset occurs at 30–90 minutes, with peak effects at 2–4 hours and after-effects persisting 2–8 hours.^[5][9] Oral bioavailability was confirmed in the earliest clinical investigations.^[7]

The primary metabolic route is MAO-A-mediated oxidative deamination. Szára's early research identified 6-hydroxy-DET as a metabolite with minor psychoactive activity — notably, the corresponding DMT metabolite (6-hydroxy-DMT) was found inactive.^[5] Liver enzymes likely contribute to indole ring hydroxylation, but the specific enzymes involved have not been mapped for DET.^[12]

Half-life, peak plasma concentration, volume of distribution, protein binding, and clearance remain uncharacterized in humans. safety citation needed

Where it acts

No direct neuroimaging or electrophysiological studies of DET have been published. As a serotonin 2A receptor agonist, DET is expected to activate receptors on cortical pyramidal neurons, disrupting default mode network integrity, reducing thalamocortical gating, and increasing both global functional connectivity and neural signal complexity. citation needed

The downstream signaling cascade — involving phospholipase C, protein kinase C, and calcium mobilization — modulates glutamate transmission and cortical excitability, producing the characteristic disruption of ordinary perceptual filtering.^[11]

Why it matters

The REBUS (Relaxed Beliefs Under Psychedelics) model provides the dominant theoretical framework: 5-HT₂A agonism reduces the precision of top-down predictions, allowing bottom-up sensory input to exert greater influence on perception and cognition. This predicts DET's reported visual generation, loosened associative thinking, and ego boundary softening at higher doses. citation needed

Classical serotonergic psychedelics also promote structural neuroplasticity through BDNF release and mTOR pathway activation. citation needed Whether DET specifically drives neuroplastic change has not been investigated, though its 5-HT₂A agonist activity makes such effects plausible.

Toxicity

No lethal dose has been established for DET in any species, and no human fatalities attributable to the compound have been reported. safety citation needed This absence likely reflects DET's uncommon use rather than confirmed safety.

Psychological risks

Acute anxiety and psychosis-like states were documented in early clinical studies using institutionalized patients under coercive conditions^[3] — these likely reflect adverse set and setting rather than a property unique to DET. Anxiety, paranoia, and thought loops are reported, particularly without appropriate preparation or environment.^[3][5]

Hallucinogen persisting perception disorder (HPPD) has not been specifically reported for DET but is a documented class-level risk for serotonergic psychedelics. Precipitation of latent psychosis is a concern for all serotonin 2A receptor agonists, particularly in individuals with personal or family history of psychotic disorders.

Tolerance and dependence

Tolerance develops rapidly — effectively after a single dose — through 5-HT₂A downregulation in the frontal cortex.^[6] This desensitization is driven by receptor internalization rather than β-arrestin2-dependent pathways.

Cross-tolerance with all classical psychedelics sharing the 5-HT₂A mechanism is expected: LSD, psilocybin, DMT, mescaline.^[6] inferred Community estimates place tolerance half-life at approximately 3 days, with full reset at approximately 7 days.

Classical psychedelics do not produce physical dependence or withdrawal. Animal studies have consistently failed to demonstrate reinforcement with classical 5-HT₂A agonist psychedelics.^[14]

Drug interactions

The most significant interaction risks are serotonergic.^[15]

Irreversible MAOIs (phenelzine, tranylcypromine) combined with DET create serious serotonin syndrome risk. Unlike DMT in ayahuasca preparations, DET does not require MAOIs for oral activity — but co-administration would substantially elevate systemic tryptamine levels.^[15]

Reversible MAOIs (moclobemide, harmaline) carry moderate risk through increased duration, intensity, and additive serotonergic load.^[15]

SSRIs present dual risk: serotonin toxicity and unpredictable modulation of the experience — either blunting or paradoxical intensification.^[15]

Lithium is a class-level contraindication, with case reports of seizures and heart rhythm disturbances documented for psychedelic–lithium combinations. citation needed

Tricyclic antidepressants carry additive serotonergic risk.

No DET-specific drug interaction studies have been published. All interaction data are class-level inferences.

Contraindications

Contraindications are inferred from the serotonergic psychedelic class. No substance-specific data exist. inferred

• Psychotic disorders (schizophrenia, schizoaffective disorder): 5-HT₂A agonism may trigger or worsen psychotic episodes. Absolute contraindication.
• Bipolar disorder with psychotic features: Risk of manic or psychotic episode. Absolute contraindication.
• Family history of psychotic disorders: Elevated risk of psychosis precipitation. Relative contraindication.
• Current lithium therapy: Documented seizure and heart rhythm risk with psychedelic co-administration. Absolute contraindication.
• Current MAOI therapy: Serotonin syndrome risk. Absolute contraindication.
• Current SSRI therapy: Unpredictable interaction and serotonin toxicity risk. Relative contraindication.
• Heart conditions: Elevated heart rate and blood pressure documented clinically. Relative contraindication.

DET is one of only five tryptamines under international control, listed in Schedule I of the 1971 Convention on Psychotropic Substances alongside DMT, etryptamine, psilocin, and psilocybin.^[4] This early inclusion reflects the compound's characterization during the first wave of psychedelic research, when clinical investigation in the late 1950s and 1960s brought it to regulatory attention. National implementations vary — some jurisdictions explicitly name DET, while others rely on structural analog provisions.

Analogue act considerations

The United States legal status requires particular attention. Although DET is not explicitly named in the Controlled Substances Act schedules, the Federal Analogue Act treats any compound "substantially similar" to a Schedule I or II substance as Schedule I if intended for human consumption. Given DET's structural similarity to DMT (a Schedule I substance) and its demonstrated psychoactive properties, prosecution under the Analogue Act is plausible. This legal ambiguity should not be interpreted as DET being unscheduled or legal in the United States. citation needed